EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study

Susan Farshi iD, Parvin Mansouri

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70187 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Susan Farshi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Alopecia Areata, Azathioprine, Immunosuppressive Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata is an autoimmune disease in which T cells may play a key role in its pathogenesis. Various immunosuppressive drugs have been employed with varying degrees of success.

Objectives

This study aimed to evaluate the long‐term efficacy and safety of azathioprine as a systemic monotherapy for moderate to severe alopecia areata.

Methods

A total of 63 patients (27 females [42.9%] and 36 males [57.1%]) with a minimum 6‐month history of alopecia areata were included. The extent of scalp hair regrowth was assessed during the treatment and annually for up to 10 years using the Severity of Alopecia Tool (SALT score). The primary endpoint was the percent change in SALT score during treatment. The daily dosage of azathioprine was calculated at 2 mg/kg of body weight.

Results

The mean duration of the current episode of scalp hair loss was 34.10 months (±39.16). The mean percentage of hair regrowth was 92.69% (±9.08). The mean percentage of hair loss decreased from 74.2% (±27.8) before treatment to 5.2% (±8.6) after 10 years of azathioprine treatment, indicating a highly significant statistical improvement (Paired t ‐test, 95% CI = 55.9–75.3). The mean hair loss score (S0–S5) improved from 5.56 (±1.3) before treatment to 0.67 (±0.53) after 10 years of treatment, showing a significant difference from the baseline score (Wilcoxon signed‐rank test, p < 0.0001).

Conclusion

This study demonstrates that azathioprine is a safe and effective systemic therapy for the treatment of recalcitrant and severe alopecia areata.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataAzathioprineImmunosuppressive AgentsHumansMaleFemaleAdultSeverity of Illness IndexTreatment OutcomeMiddle AgedHairYoung AdultFollow-Up StudiesTime FactorsAdolescent

Stichwörter der Autor:innen

alopecia areataazathioprinethiopurine methyltransferase

Substanzen

AzathioprineImmunosuppressive Agents

Autor:innen und Institutionen

  • Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Susan Farshi

Zitieren

APA

Farshi, S., & Mansouri, P. (2025). Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70187

Vancouver

Farshi S, Mansouri P. Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70187

BibTeX
@article{Farshi2025,
  author = {Farshi, Susan and Mansouri, Parvin},
  title = {Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70187}
}
Kostenlos starten →